HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Domenico Ribatti Selected Research

EZN-2208

9/2011Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
10/2010Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Domenico Ribatti Research Topics

Disease

178Neoplasms (Cancer)
05/2022 - 02/2002
40Multiple Myeloma
01/2021 - 04/2002
22Neuroblastoma
11/2018 - 07/2003
18Inflammation (Inflammations)
01/2022 - 07/2003
18Melanoma (Melanoma, Malignant)
01/2022 - 09/2002
16Hypoxia (Hypoxemia)
09/2016 - 09/2002
11Breast Neoplasms (Breast Cancer)
12/2021 - 07/2009
11Neoplasm Metastasis (Metastasis)
06/2017 - 10/2003
10B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
03/2016 - 08/2003
8Lymphoma (Lymphomas)
07/2022 - 08/2008
8Necrosis
07/2021 - 04/2002
7Fibrosis (Cirrhosis)
12/2021 - 08/2015
7Non-Hodgkin Lymphoma (Lymphosarcoma)
07/2020 - 08/2005
6Disease Progression
01/2021 - 07/2004
6Monoclonal Gammopathy of Undetermined Significance
01/2021 - 09/2009
6Adenocarcinoma
11/2017 - 12/2005
6Carcinoma (Carcinomatosis)
03/2013 - 05/2005
5Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
07/2022 - 11/2014
5Glioblastoma (Glioblastoma Multiforme)
01/2022 - 12/2009
5Wounds and Injuries (Trauma)
01/2021 - 05/2007
5Pterygium
01/2018 - 05/2007
5Pathologic Neovascularization
01/2017 - 01/2008
5Anemia
11/2014 - 11/2002
5Paraproteinemias (Monoclonal Gammopathy)
02/2014 - 02/2003
4Carcinogenesis
12/2021 - 09/2008
4Autoimmune Diseases (Autoimmune Disease)
12/2021 - 02/2013
4Renal Cell Carcinoma (Grawitz Tumor)
01/2019 - 12/2014
4Glioma (Gliomas)
10/2014 - 06/2010
3Neurodegenerative Diseases (Neurodegenerative Disease)
01/2022 - 04/2014
3Retinal Neovascularization
01/2020 - 07/2013
3Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)
10/2019 - 05/2003
3Pancreatic Neoplasms (Pancreatic Cancer)
03/2019 - 12/2011
3Stomach Neoplasms (Stomach Cancer)
08/2018 - 08/2010
3Endometrial Neoplasms (Endometrial Cancer)
02/2017 - 12/2005
3Colorectal Neoplasms (Colorectal Cancer)
01/2016 - 10/2004
3Globoid Cell Leukodystrophy (Krabbe Disease)
10/2015 - 09/2013

Drug/Important Bio-Agent (IBA)

57Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2022 - 09/2002
33CytokinesIBA
02/2022 - 02/2003
20Tryptases (Tryptase)IBA
03/2021 - 08/2003
18Biological ProductsIBA
07/2022 - 10/2004
17Pharmaceutical PreparationsIBA
07/2021 - 10/2005
17Proteins (Proteins, Gene)FDA Link
01/2021 - 08/2002
15Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
09/2019 - 12/2004
12Angiogenesis InhibitorsIBA
10/2020 - 02/2003
10Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2019 - 02/2002
10Monoclonal AntibodiesIBA
08/2018 - 10/2003
9ErythropoietinFDA Link
01/2019 - 05/2007
9Bortezomib (Velcade)FDA Link
03/2018 - 01/2006
8Biomarkers (Surrogate Marker)IBA
01/2022 - 08/2008
8AntibodiesIBA
10/2021 - 12/2009
8LigandsIBA
01/2020 - 10/2006
8Peptides (Polypeptides)IBA
11/2018 - 11/2003
7Liposomes (Liposome)IBA
11/2018 - 10/2003
6ChemokinesIBA
01/2019 - 02/2003
6Doxorubicin (Adriamycin)FDA LinkGeneric
11/2018 - 10/2006
6Matrix Metalloproteinases (MMPs)IBA
09/2015 - 12/2004
6Therapeutic UsesIBA
03/2015 - 07/2007
5Messenger RNA (mRNA)IBA
01/2022 - 09/2002
5Oxygen (Dioxygen)IBA
01/2022 - 07/2008
5Protein Isoforms (Isoforms)IBA
10/2019 - 12/2004
5Bevacizumab (Avastin)FDA Link
01/2019 - 01/2006
5CD13 Antigens (Alanine Aminopeptidase)IBA
09/2013 - 11/2003
5Interleukin-12 (IL 12)IBA
11/2011 - 03/2007
5Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
01/2008 - 12/2004
4RNA (Ribonucleic Acid)IBA
01/2022 - 07/2008
4AntigensIBA
01/2022 - 11/2003
4Transforming Growth Factors (Transforming Growth Factor)IBA
03/2021 - 06/2017
4EnzymesIBA
11/2020 - 08/2002
4GalactosylceramidaseIBA
11/2020 - 09/2013
4Interleukin-6 (Interleukin 6)IBA
09/2020 - 07/2009
4MicroRNAs (MicroRNA)IBA
01/2020 - 06/2009
4SuspensionsIBA
01/2019 - 08/2006
4Aquaporins (Water Channels)IBA
01/2019 - 08/2010
4Vascular Endothelial Growth Factor CIBA
01/2018 - 07/2009
4Angiogenesis Inducing Agents (Angiogenesis Factor)IBA
10/2016 - 12/2004
4Tyrosine Kinase InhibitorsIBA
01/2016 - 04/2007
4Nerve Growth Factor (NGF)IBA
05/2014 - 08/2002
4FenretinideIBA
09/2013 - 07/2003
3Phenobarbital (Luminal)FDA Link
01/2022 - 05/2011
3Cadherins (E-Cadherin)IBA
12/2021 - 12/2015
3Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
01/2021 - 02/2017
3InterleukinsIBA
09/2020 - 04/2005
3DystrophinIBA
10/2019 - 05/2003
3PTX3 proteinIBA
09/2019 - 01/2013
3Chymases (Chymase)IBA
08/2019 - 08/2010
3Metalloproteases (Metalloproteinases)IBA
01/2019 - 12/2005
3Coloring Agents (Dyes)IBA
11/2018 - 08/2010
3Platelet-Derived Growth FactorIBA
08/2018 - 09/2008
3Angiopoietin-1IBA
08/2018 - 05/2009
3Transcription Factors (Transcription Factor)IBA
04/2018 - 09/2002
3NestinIBA
01/2018 - 01/2010
3Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
10/2017 - 04/2007
3Peptide Hydrolases (Proteases)FDA Link
02/2017 - 02/2002
3Psychosine (Galactosylsphingosine)IBA
10/2015 - 09/2013
3Serine Proteases (Serine Protease)IBA
03/2015 - 07/2009
3Cisplatin (Platino)FDA LinkGeneric
12/2014 - 05/2005

Therapy/Procedure

67Therapeutics
07/2022 - 02/2003
13Drug Therapy (Chemotherapy)
01/2019 - 11/2003
4Immunotherapy
01/2022 - 11/2008
4Radiotherapy
12/2015 - 09/2008